Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2023 Mar 9.

Published in final edited form as: Expert Opin Investig Drugs. 2022 Aug 3;31(9):875–879. doi: 10.1080/13543784.2022.2108588

Figure 2. — (a) Twelve days post GL261 inoculation, mice were treated with 5 × 10⁸ plaque- forming units (pfu) of adenoviral (Ad)-Flt3L and 1.0 × 10⁸ pfu of Ad-TK followed by the administration of ganciclovir. Mice were treated with CD200AR-L (2.5 mg/kg) (s.c.) twice weekly for 4 weeks. PD-L1-neutralizing or CTLA-4-blocking antibodies were administered twice, 6d and 11d post gene therapy; animals were monitored for survival. Experiments were performed separately with appropriate controls. **p < 0.01, ***p < 0.005, by log-rank (Mantel-Cox) test, MS, median survival. Breast carcinoma mice were vaccinated weekly with CD200AR-L + autologous tumor lysates. Mice were imaged weekly and monitored for (b-e) tumor growth and (f) Survival. (g) Mice were rechallenged in the contralateral fat pad with and monitored for 14 days for tumor growth.

Figure 2. — (a) Twelve days post GL261 inoculation, mice were treated with 5 × 10⁸ plaque- forming units (pfu) of adenoviral (Ad)-Flt3L and 1.0 × 10⁸ pfu of Ad-TK followed by the administration of ganciclovir. Mice were treated with CD200AR-L (2.5 mg/kg) (s.c.) twice weekly for 4 weeks. PD-L1-neutralizing or CTLA-4-blocking antibodies were administered twice, 6d and 11d post gene therapy; animals were monitored for survival. Experiments were performed separately with appropriate controls. **p < 0.01, ***p < 0.005, by log-rank (Mantel-Cox) test, MS, median survival. Breast carcinoma mice were vaccinated weekly with CD200AR-L + autologous tumor lysates. Mice were imaged weekly and monitored for (b-e) tumor growth and (f) Survival. (g) Mice were rechallenged in the contralateral fat pad with and monitored for 14 days for tumor growth.